Beta-glucooligosaccharide-containing composition, and method of improving intestinal flora

Abstract: A composition for oral ingestion characterised in that it comprises at least one β-oligosaccharide and/or a reduced product thereof for improving intestinal flora and for use as a low calorie flavouring agent.

Description: The present invention relates to a nutritional or medicinal composition which comprises at least one β-glucooligosaccharide and/or a reduced product thereof, and to a method of improving intestinal flora, using a β-glucooligosaccharide and/or a reduced product thereof as an active ingredient. In the manufacture of various types of food and drink, a variety of saccharides such as sucrose, corn starch syrup, glucose, maltose and high-fructose corn syrup have been used as sweeteners. However, these saccharides, which are formed from the monosaccharides glucose, fructose or a sugar formed by α-glucosidic linkage of glucose monomers are digested by living organisms and accumulated as calorific sources, and thus have the problem that an excessive intake thereof may cause obesity or may bring about adult diseases such as diabetes. Non-calorific synthetic sweeteners such as Aspartame have also been developed. Since, however, synthetic sweeteners are not natural products, there is concern about their safety to the human body. Some non-synthetic, α-glucooligosaccharides have been identified as compounds useful as calorie-free carriers (see EP-A-164656). The β-glucooligosaccharide, cellobiose has been found to have a similar application (see JP-A-62273921). A further β-glucooligosaccharide, sophorose has been attributed with sweetening properties (see JP-A-63116668). In view of the recent trend of taste in food and drink, people avoid sweetness more than ever, and food and drink seasoned only with a sweetener is not usually acceptable. On the other hand, in recent years, intestinal flora (the aggregate of bacteria) is known to affect the health of humans, and there is an increasing interest in the intestinal flora. For example, Bifidobacteria are one of the main bacterial species that constitute human intestinal flora, and are known, for example, to inhibit the growth of putrefactive and pathogenic bacteria, thus performing a variety of useful physiological roles in humans and animals. The Bifidobacteria may decrease or disappear as a result of various diseases or aging, and hence attempts have been made to increase Bifidobacteria in the intestine. Food or medicine suited for such a purpose includes, for example, yoghurt containing Bifidobacteria, powder of Bifidobacteria, and oligosaccharides capable of supporting the growth of Bifidobacteria. Of these, the oligosaccharides capable of growing Bifidobacteria have recently become prominent. Fructooligosaccharide, soyabean oligosaccharide, konjak oligosaccharide, isomaltooligosaccharide, galactooligosaccharide, and so forth have been reported to support the growth of Bifidobacteria. Some of these have already been made commercially available as health food materials. Lactic acid bacteria (or Lactobacilli) have been previously known to be useful bacteria that affect intestinal flora. The lactic acid bacteria, like Bifidobacteria, are also considered to play a role in inhibiting intestinal growth of putrefactive bacteria. Thus, viable lactic acid bacteria have been mixed in an intestinal regulator, and drinks containing lactic acid bacteria are commercially available. The effect of promoting the growth of Bifidobacteria, attributable to the oligosaccharides described above, is caused by the action of Bifidobacteria which can decompose the oligosaccharides and utilize them as nutrient sources; since most other bacteria cannot decompose the oligosaccharides, the Bifidobacteria grow selectively. These oligosaccharides, however, support the growth of various bacteria and are not necessarily selectively utilized only by Bifidobacteria. Bacterial species vary in the types of oligosaccharides they can utilise. At present, this can only be experimentally determined. The intestinal flora comprise a mixed population of bacteria. Even when the Bifidobacteria become temporarily predominant in the intestine, their influence may rapidly change. Thus, it is preferred to promote the growth of not only Bifidobacteria but also other useful bacteria such as lactic acid bacteria in order to stably maintain the effect of improving intestinal flora. In other words, the influence of lactic acid bacteria and so forth may also be increased together with that of Bifidobacteria, so that the effect of inhibiting the growth of putrefactive bacteria such as Welch bacilli ( Clostridium perfringens ) can be maintained in a stable state. Previous investigations into the improvement in intestinal flora by the use of oligosaccharides have been mainly focused only on the action of promoting the growth of Bifidobacteria. There has been little study on the effect on other useful bacteria such as lactic acid bacteria. EP-A-242459 describes the use of α-glucooligo-saccharides for selectively promoting the proliferation of intestinal bifidobacteria, but these compounds did not promote the growth of Lactobacillus acidophilus . Lactic acid bacteria have previously been added to intestinal regulators and drinks, but not however with the aim of improving the growth of lactic acid bacteria in the intestine. Hence, even if the influence of lactic acid bacteria is temporarily increased by ingestion of living bacteria, no stable effect of improving intestinal flora can be expected since their influence may readily change because of the presence of other bacteria which are better adapted to the environment. There is thus a need for new compositions for improving intestinal flora and for modifying the flavour of food and drink yet having a low calorific value. To achieve these aims, the present inventors made studies on various saccharides to examine their effects of imparting a novel flavour and improving intestinal flora. As a result, they have found that β-glucooligosaccharides are non-calorific, have a pleasant bitter taste, and also have an excellent effect of improving intestinal flora. Thus, according to one aspect, the present invention provides a medicinal composition for oral ingestion characterised in that it comprises at least one β-glucooligosaccharide and/or a reduced product thereof for use in promoting the growth of intestinal flora including Bifidobacteria and Lactobacillus acidophilus . According to a further aspect, the present invention provides the use of a β-glucooligosaccharide and/or a reduced product thereof in the manufacture of nutritional or medicinal compositions for improving intestinal flora. The β-glucooligosaccharide herein referred to are saccharides comprising glucose molecules linked by β-1,6-glucosidic and/or β-1,4-glucosidic bonds. The reduced products thereof may be obtained by catalytic reduction (or hydrogenation) of a β-glucooligosaccharide. These are safer to the human body than synthetic sweeteners. The β-glucooligosaccharides also have a characteristic bitter taste. The reduced product thereof lose the bitter taste to render a pleasant and mild sweet taste. Thus, these compounds may be added to food and drink and so forth to modify the flavour by imparting various pleasant tastes, that have not been achieved by conventional sweeteners. In addition, the β-glucooligosaccharides and the reduced products thereof have a low calorific value since they are not metabolised by animals, and hence it is possible to prevent obesity and adult diseases that may be caused by an excessive calorific intake. As will be evident from the experimental results described later, the β-glucooligosaccharides and the reduced products thereof are not only well utilized by Bifidobacteria but also well utilized by lactic acid bacteria. Moreover, harmful bacteria such as Welch bacilli ( Clostridium perfringens ) as well as other putrefactive bacteria can not utilize these oligosaccharides and can not grow well. Thus, ingestion of the β-glucooligosaccharides and/or the reduced products thereof may bring about promotion of the selective growth of physiologically useful bacteria such as Bifidobacteria and lactic acid bacteria, inhibition of the growth of harmful or putrefactive bacteria, and hence improvement in the intestinal flora. The present invention will be described below in detail by giving preferred embodiments and with reference to the attached drawings in which Fig. 1 is a graph to show elution patterns obtained when a crude cellulase preparation was subjected to Amberlite CG-50 column chromatography; Fig. 2 is a graph to show elution patterns obtained when a Peak III fraction of the above was subjected to gel filtration chromatography using Bio-Gel P-60; and Fig. 3 is a graph to show elution patterns obtained when a β-glucosidase active fraction of the above was subjected to isoelectric focusing by the use of an LKB 110 ml column. The β-glucooligosaccharides used in the present invention may be readily produced in a high yield by, for example, action of a β-glucosidase originating from a variety of microorganisms on glucose and/or a β-glucooligosaccharide, utilising the condensation and transglycosylation activities of the enzyme preferably under optimal conditions for oligosaccharide synthesis. Any β-glucosidase originating from a variety of microorganisms may be used in the production of the β-glucooligosaccharides. For example, those preferred are enzymes originating from microorganisms such as mold fungi Trichoderma viride , Trichoderma reesei , Trichoderma koningii , Aspergillus niger and Penicillium frequentans ; wood-rotting fungi Polypolus tulipiferae , Chrysosprium lignorum and Shizophyllum commune ; and bacteria Pseudomonas fluorescens var. cellulosa , Cellulomonas uda , Clostridium thermocellum and Ruminococcus albus . These microorganisms are all known in the art, and are readily available for the preparation of the enzymes. As a substrate, at least one of D -glucose and β-glucooligosaccharide may be used. Here, the β-glucooligosaccharide serving as a substrate refers to cellobiose, gentiobiose, or a gentiooligosaccharide having a higher degree of polymerization. When the β-glucooligosaccharide is used as a substrate, a β-glucooligosaccharide with a higher degree of polymerization may be obtained by the present enzymatic reaction. In a particularly preferred embodiment, at least one selected from glucose, cellobiose and gentiobiose is used as the substrate. The β-glucosidase may be made to act on glucose and/or a β-glucooligosaccharide, whereby a β-glucooligosaccharide of various types such as cellobiose, sophorose, laminaribiose, gentiobiose, a 4- O -β- D -gentiooligosyl- D -glucose and a 6- O -β- D -gentiooligosyl- D -glucose may be obtained. Here, the 4- O -β- D -gentiooligosyl- D -glucose refers to 4- O -β- D -gentiobiosyl- D -glucose, 4- O -β- D -gentiotriosyl- D -glucose, or a saccharide having a higher degree of polymerization than these. The 6- O -β- D -gentiooligosyl- D -glucose also refers to 6- O -β- D -gentiobiosyl- D -glucose (gentiotriose), 6- O -β- D -gentiotriosyl- D -glucose (gentiotetraose), or a saccharide having a higher degree of polymerization than these. These reaction products may vary depending on the enzymes used. When glucose or cellobiose is used as a substrate, the above β-glucooligosaccharide of various types tends to be produced as a mixture of several kinds. When gentiobiose is used as a substrate, only a gentiooligosaccharide such as 6- O -β- D -gentiobiosyl- D -glucose or 6- O -β- D -gentiotriosyl- D -glucose tends to be formed as a reaction product. Conditions for the enzymatic reaction will be described below. There are no particular limitations on the concentration of the substrate. In usual instances, it may preferably be in the range of from 1 to 90% weight/volume), and more preferably from 5 to 80% weight/volume). Higher concentrations of enzyme relative to substrate are preferred. In usual instances, the enzyme may preferably be used in a concentration of not less than 100 mg per gram of the substrate. The reaction may be carried out under optimum temperature and pH conditions for the enzymes used. In usual instances, the reaction may preferably be carried out at a temperature of from 30 to 80°C, and at a pH of approximately from 3 to 8. Reaction time may be so set as to be the time during which a sufficient amount of the desired β-glucooligosaccharide can be produced and accumulated. In usual instances, the reaction may suitably be carried out approximately for 2 to 72 hours. The reaction may be carried out by adding the enzyme to the substrate. Alternatively, the reaction may be carried out by a continuous reaction method in which the enzyme is adsorbed on a suitable immobilizing agent to form an immobilized enzyme and the resulting immobilized enzyme is used. The reaction product thus prepared may further be fractionated by various known methods so that β-glucooligosaccharides of various kinds can be respectively separated and purified. In the present invention, reduced products of the β-glucooligosaccharides thus obtained may also be used. The reduced product may be obtained by subjecting a β-glucooligosaccharide to catalytic reduction (or hydrogenation). Such a treatment is well known in the production of sugar alcohols. The β-glucooligosaccharide-containing composition of the present invention may be obtained by adding the β-glucooligosaccharide and/or the reduced product thereof to a nutritional material such as food, drink or medicine in the course of producing such materials. In this way, the β-glucooligosaccharidesand/or the reduced products thereof may be added to food, drink or medicine, so that it is possible to impart an appropriately bitter taste or a mild sweet taste which have not been achieved by conventional saccharides, thus bringing about the effect of improving tastes. Since the β-glucooligosaccharides and the reduced products thereof are not digestible by animals, a dietary effect may also be obtained. In addition, since the β-glucooligosaccharides and the reduced products thereof are rich in moisture retention, they are also effective as humectants, anti-crystallization agents, or agents for imparting gloss, body or the like. In the present invention, the β-glucooligosaccharides and/or the reduced products thereof are also utilized as a substance for improving intestinal flora . More specifically, the β-glucooligosaccharide and/or the reduced product thereof may be ingested as health foods or medicines alone, or may be added to a material such as food, drink or medicine, so that the growth of Bifidobacteria and lactic acid bacteria in the intestine can be promoted, the growth of harmful bacteria can be inhibited and thus the intestinal flora can be maintained in a good condition. In the compositions of the present invention, only the β-glucooligosaccharides and/or the reduced products thereof may be added as a taste improver. Since, however, the sweet taste tends to be a little low, the β-glucooligosaccharidesand/or the reduced products thereof may be used in combination with one or more kinds of other sweeteners as exemplified by sucrose, corn syrup, glucose, maltose, high-fructose corn syrup, honey, sorbitol, maltitol, lactitol, L-aspertylphenylalanine methyl ester (Aspartame), saccharin, glycyrrhizin, and stevioside. In the present invention, the food and drink to which the β-glucooligosaccharide and/or the reduced product thereof is/are added includes various seasonings as exemplified by soy sauce, mayonnaise, dressing, vinegar, an instant Chinese food mix, soup for tempura (fried food), sauce, catchup, gravy for grilled meat, curry roux, an instant stew mix, an instant soup mix, an instant broth mix, a composite seasoning, and mirin (sweet sake for seasoning). It also includes all sorts of food and drink or favorite food as exemplified by Japanese-style confections such as arare (rice-cake cubes), mochi (rice cakes), manju (bean-jam buns), uiro (sweet rice jelly), an (bean paste or jam), yokan (sweet bean jelly), jelly, castella (sponge cake), and Japanese candies Western-style cakes such as bunds, biscuits or crackers, cookies, pies (or tarts), pudding, butter cream, cream puffs, sponge cake, doughnuts, chocolate, chewing gum, caramels, and hard candies; ices such as ice cream, and sherbet; fruits preserved in syrup; syrups such as ice molasses; pastes such as flour paste, peanut paste, and fruit paste; processed fruits such as jam, marmalade, syrupped fruits, and sweetmeats; pickles such as fukujin-zuke (sliced vegetables pickled in soy sauce), senmai-zuke (pickled turnips), and rakkyo-zuke (pickled scallions); meat products such as ham, and sausage; fish products such as kamaboko (boiled fish paste), and chikuwa (fish paste hollow-rods); all sorts of dilicacies; tsukudani (food boiled down in soy sauce); alcohol such as beer, liqueur, and sake (rice wine); drinks or soft drinks (or aerated drinks) such as coffee, cocoa, juice, carbonated drink, drink preparations, lactic acid drink, and lactic acid bacteria drink; and instant food and drink such as instant juice, and instant coffee. The β-glucooligosaccharides and/or the reduced productsthereof may also be mixed with other biologically active substances such as dietary fiber, lactic acid bacteria, Bifidobacteria, and vitamins to give health foods or medicines. When added to food, drink or medicine, the β-glucooligosaccharides and/or the reduced products thereof may preferably be in an amount of from 0.5 to 50% by weight, and more preferably from 1.0 to 30% by weight, in order to achieve the effect of improving tastes or improving intestinal flora as stated above. The present invention will now be described in greater detail by the following non-limiting Examples. Example 1 (Production of β-glucooligosaccharide) (1) In 200 mℓ of a 0.2 M acetate buffer (pH 3.5), 5 g of a crude cellulase preparation "Meiselase" (trade name; a product of Meiji Seika Kaisha Ltd.) originating from mold fungi Trichoderma viride was dissolved. The solution was then subjected to column chromatography using Amberlite CG-50. Fig. 1 shows the elution patterns thus obtained. In Fig. 1, the line with black triangles indicates amylase activity; the line with white circles, Avicel-saccharification activity; the line with black circles, CMC-saccharification activity; the line with "x", β-glucosidase activity; and the line with dots, amount of protein. In this way, a fraction Peak II showing a strong cellulase activity and a fraction Peak III showing a strong β-glucosidase activity were separated. The fraction Peak III was collected and further subjected to gel filtration chromatography using Bio-Gel P-60 to obtain the elution patterns as shown in Fig. 2. In Fig. 2, the line with white circles indicates Avicel-saccharification activity; the line with black circles, β-glucosidase activity; the line with black triangles, CMC-saccharification activity; and the line with dots, amount of protein. From the resulting eluate, a fraction having β-glucosidase activity was collected. Next, the above β-glucosidase-active fraction was subjected to isoelectric focusing using an LKB 110 mℓ column to obtain the purified β-glucosidase (Fig. 3). In Fig. 3, the line with white circles indicates Avicel-saccharification activity; the line with black circles, glucosidase activity; the line with black triangles, CMC-saccharification activity; and the line with dots, amount of protein. The isoelectric focusing was carried out using a carrier Ampholite with pH 4 to 6, and under electrophoresis conditions of 5 mA, 600 V (at the time of start) to 1.5 mA, 1,500 V (at the time of completion). From the resulting eluate, a fraction having β-glucosidase activity was collected. The final purified enzyme preparation was thus obtained. The purified enzyme thus obtained gave a single protein band as a result of polyacrylamide gel electrophoresis (PAGE) and SDS-PAGE. The resulting enzyme, as shown in Fig. 3, has a potent β-glucosidase activity, and, even though very weak, the enzyme also shows both Avicel- and CMC-saccharification activities. The enzyme activity was measured by carrying out the reaction under conditions of pH 5.0 and a temperature of 30°C, using p-nitrophenyl β- D -glucosidase (β-PNPG). One unit of enzyme activity was defined as the amount of enzyme that catalyses the liberation of reduing sugar equivalent to 1.0 µmol of D -glucose from the substrate per min. under the above conditions. (2) To 300 g of D -glucose, the purified β-glucosidase in the above was added in a an amount of 5.8 x 10⁵ unit (500 mℓ) (glucose: about 60% w/v), and the reaction was carried out at pH 5.0 and a temperature of 60°C. After completion of the reaction, the reaction mixture was heated at 100°C for 5 minutes to stop the reaction, decolored with activated carbon according to a conventional method, and purified by deionization, followed by concentration to a solid content of 72% (w/w) under reduced pressure. After a column with a jacket of 2 cm in inner diameter and 120 cm in length (60°C) was packed with a cationic ion-exchange resin "Dowex 99" (Na⁺ type; a product of Dow Chemical Co., the reaction product saccharide solution thus obtained was loaded so as to give a solid content of from 5 to 7% (w/v) based on the amount of resin, and fractionated at a space velocity (SV.hr⁻¹) of 0.35 to obtain a gentiooligosaccharide fraction (OS-1). Saccharide composition of this fraction was analyzed by high-performance liquid chromatography to obtain the results as shown in Table 1. The analysis by the high-performance liquid chromatography was carried out under the following conditions: Column: SCR-101, manufactured by Shimadzu Corporation Detector: A differential refractometer Column temperature: 55°C Column flow rate: 0.8 mℓ/min The above operation was carried out 10 times to give about 40 g of gentiooligosaccharide (OS-1). The product was freeze-dried and formed into powder. (3) The above gentiooligosaccharide (OS-1) was further fractionated in the same manner as in the above. A fraction of β-glucodisaccharide (F-2), a fraction of β-glucotrisaccharide (F-3) and a fraction of β-glucotetra(or more)saccharide (F-4) were thus obtained. The saccharide composition of these fractions were analyzed by high-performance liquid chromatography to obtain the results as shown in Table 1. In the foregoing, the β-glucodisaccharide refers to a disaccharide comprising a β-glucoside bond, as exemplified by cellobiose, sophorose, laminaribiose, or gentiobiose. The β-glucotrisaccharide refers to 4- O -β- D -gentiobiosyl- D -glucose, 6- O -β- D -gentiobiosyl- D -glucose (gentiotriose), etc. The β-glucotetra(or more)saccharide refers to 4- O -β- D -gentiotriosyl- D -glucose or a saccharide having a higher degree of polymerization, 6- O -β- D -gentiotriosyl- D -glucose or a saccharide having a higher degree of polymerization. (Saccharide composition of OS-1, F-2, F-3, F-4) Percentage by weight OS-1 F-2 F-3 F-4 Fructose (F): 3.1 0 0 0.2 Glucose (G): 11.8 1.2 0.5 2.7 β-glucodisaccharide (G₂): 52.8 93.6 0 0 β-glucotrisaccharide (G₃): 22.1 5.1 90.3 0.3 β-glucotetra(or more)saccharide (G₄): 10.2 0.1 9.2 96.8 Example 2 (Tests on utilization by intestinal bacteria) Utilization of each oligosaccharide by intestinal bacteria was tested in the following way: (1) Strains tested: Used were 17 strains of Bacteroides , 20 strains of Bifidobacterium , 26 strains of Clostridium , 6 strains of Eubacterium , 5 strains of Fusobacterium , 6 strains of Peptstreptococcus , 9 strains of Lactobacillus , 5 strains of Enterococcus , 5 strains of Escherichia coli , and 21 strains of others, i.e, 120 strains in total. (2) Test groups: 1. Control (no carbohydrate added) 2. Glucose 3. Meioligo-P (trade name; a commercially available fractooligosaccharide; a product of Meiji Seika Kaisha, Ltd. 4. OS-1 (a β-glucooligosaccharide fraction) 5. F-2 (a β-glucodisaccharide fraction) 6. F-3 (a β-glucotrisaccharide fraction) 7. F-4 (a β-glucotetra(or more)saccharide fraction) In the foregoing, Meioligo-P has the following saccharide composition: Sucrose (GF) ... 4% by weight 1-Kestose (GF2) ... 35% by weight Nystose (GF3) ... 50% by weight 1-Fractosylnystose (GF4) ... 11% by weight (3) Culture medium: To a semi-fluid agar medium of a Pepton-Yeast-Fildes solution (PYF), each saccharide of the test groups was added so as to finally give a concentration of 0.5%, and the medium was used after autoclave sterilization at 115°C for 20 minutes. In the foregoing, the PYF semi-fluid agar medium has the following composition: Trypticase (BBL) 10.0 g Yeast extract (Difco) 10.0 g Fildes solution 40.0 mℓ Salts solution 40.0 mℓ L-systin hydrochloride monohydrate 0.5 g Agar 1.5 g Deionized water 920 mℓ In the forefoing, the salts solution has the following composition: CaCl₂, anhydrous 0.2 g MgSO₄ 0.2 g K₂HPO₄ 1.0 g KH₂PO₄ 1.0 g NaHCO₃ 10.0 g NaCl 2.0 g Deionized water 1,000 mℓ (4) Test method: Frozen strains for the test were each streak-cultured in a BL agar medium to obtain isolated colonies. This operation was carried out twice to obtain pure-cultured strains. A BL agar plate used was obtained by adding 5% of equine defibrinated blood produced by Kohjin Co., Ltd., to a BL agar medium produced by Nissui Chemical Industries, Ltd. Culture was carried out using an anaerobic incubator manufactured by Sanyo-Forma Co. The strains tested thus obtained by pure culture were inoculated on a Fildes solution-added GAM broth culture medium (obtained by adding 0.4% of a Fildes solution to a GAM broth produced by Nissui Chemical Industries, Ltd.), and subcultured by anaerobic culture at 37°C for 24 hours using an anaerobic incubator manufactured by Sanyo-Forma Co. The resulting culture solution was inoculated in 1.5 mℓ of the above test culture medium in an amount of 0.03 mℓ, using an automatic multi-strain inoculating apparatus "MD-120", manufactured by LIFETEC CO., and cultured at 37°C for 4 days (96 hours) under anaerobic conditions. Thereafter, the pH was measured. After inoculation, the inoculated strain solution was inspected to see whether or not contamination or poor growth occurred, and those pertinent thereto were removed from data. The anaerobic culture was carried out using the anaerobic incubator manufactured by Sanyo-Forma Co., and in an atmosphere of a mixed gas of 10% of CO₂, 10% of H₂ and the balance of N₂. The pH was measured and the data were processed, using "BIS-120", manufactured by LIFETEC CO. (5) Judgement on utilization: A decrease in the pH value of the culture was measured, and the occurrence or strength of utilization was judged. Judgement was made according to the following criteria: - : pH 6.0 or more: ±: pH 5.5 to less than 6.0 +: pH 5.0 to less than 5.5 ++: pH 4.5 to less than 5.0 +++: less than pH 4.5 (6) Test results: Test results obtained are shown in Table 2. Table 2 shows the following: (i) With regard to Bacteroides , all the test groups show substantially the same value of utilization. (ii) With regard to Bifidobacterium , all the test groups show a strong value of utilization as a whole. With regard to Bifidobacterium bifidum , no utilization is seen on Meioligo-P, F-3 and F-4, but utilization is confirmed on OS-1 and F-2 which contain β-glucodisaccharide. (iii) With regard to Clostridium , utilization is seen on glucose in many cases, but no utilization is seen on Meioligo-P, OS-1, F-2, F-3 and F-4 in almost all cases. (iv) With regard to Eubacterium , Fusobacterium , Pepststreptococcus and Escherichia coli , no utilization is seen on Meioligo-P, OS-1, F-2, F-3 and F-4 in many cases. (v) With regard to Lactobacillus , no utilization is seen on Meioligo-P in many cases, but utilization is seen on OS-1, F-2, F-3 and F-4 in considerably many cases. In particular, with regard to Lactobacillus casei , no utilization is seen at all on Meioigo-P, but a strong value of utilization can be seen on OS-1, F-2, F-3 and F-4. It is clear from the above results that OS-1, F-2, F-3 and F-4 comprising a β-glucooligosaccharide are well utilized by not only Bifidobacteria but also lactic acid bacteria, and can be utilized with difficulty by other pathogenic bacteria or putrefactive bacteria. Hence, the ingestion of these β-glucooligosaccharides is seen to enable promotion of the selective growth of Bifidobacteria and lactic acid bacteria, inhibition of the growth of pathogenic bacteria or putrefactive bacteria, and improvement in the intestinal floras. The same results as the above were obtained also when reduced gentiooligosaccharides were used. (Test results on utilization) Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Bacteroides asaccharolyticus GAI# 25260 - - - - - - - Bacteroides bivius GAI# 5518 - ++ - ++ ++ + + Bacteroides distasonis GAI# 5462 - + ± + + ± ± Bacteroides fragilis GAI# 5524 - + + ++ ++ + + Bacteroides fragilis GAI# 5562 - ++ + ++ ++ ++ + Bacteroides fragilis R-18 - ++ + ++ ++ ++ + Bacteroides intermedius 46 Bacteroides ovatus JCM 5824 - ++ + ++ ++ ++ + Bacteroides ovatus CIFL N0029 - ++ ++ +++ ++ + + Bacteroides thetaiotaomicron GAI# 5628 - + + ++ ++ + + Bacteroides thetaiotaomicron VI-98 - + + ++ ++ ++ + Bacteroides uniformis GAI# 5466 - + + + + + + Bacteroides vulgatus GAI# 5460 - ++ ± + + ± ± Bacteroides vulgatus R-16 - ++ - + + + + Bacteroides vulgatus B-25 - ++ + + + + ± Bacteroides vulgatus B-84 - ++ + + + + ± Bacteroides vulgatus V-114 - ++ ± +++ + ± ± Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Bifidobacterium adolescentis CIFL N0035 - +++ ++ +++ +++ +++ +++ Bifidobacterium adolescentis CIFL N0037 - +++ +++ +++ +++ +++ +++ Bifidobacterium adolescentis CIFL N0038 - +++ +++ +++ +++ +++ +++ Bifidobacterium adolescentis CIFL N0042 - +++ +++ +++ +++ +++ +++ Bifidobacterium adolescentis CIFL N0046 - +++ +++ +++ +++ +++ +++ Bifidobacterium adolescentis aE194a - +++ +++ +++ +++ +++ +++ Bifidobacterium animalis CIFL N0040 - +++ + +++ +++ +++ +++ Bifidobacterium bifidum R-2 - +++ - +++ ++ - - Bifidobacterium bifidum aE318 - +++ - ++ ++ - - Bifidobacterium breve bs46 - +++ ++ +++ +++ +++ +++ Bifidobacterium breve as50 - +++ ++ +++ +++ +++ +++ Bifidobacterium breve IV-14 - +++ ++ +++ +++ +++ +++ Bifidobacterium breve IV-19 - +++ ++ +++ +++ +++ +++ Bifidobacterium infantis S-12 - +++ +++ +++ +++ +++ +++ Bifidobacterium infantis CIFL N0044 - +++ ++ +++ +++ +++ +++ Bifidobacterium longum CIFL N0036 - +++ + +++ +++ +++ +++ Bifidobacterium longum CIFL N0044 - +++ + +++ +++ +++ +++ Bifidobacterium longum aE194b - +++ ++ +++ +++ +++ +++ Bifidobacterium longum R-3 - +++ ++ +++ +++ ++ ++ Bifidobacterium longum M101-2 - +++ + +++ +++ +++ ++ Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Clostridium butyricum GAL# 7503 - +++ ++ ++ ++ ++ ++ Clostridium butyricum Rw23 - +++ ++ +++ +++ ++ ++ Clostridium cadaveris XI-10 - + - - - - - Clostridium clostridioforme GAI# 5458 - + ± ± ± - - Clostridium clostridioforme R-14 - + - - - - - Clostridium difficile GAI# 10038 - ± - - - - - Clostridium difficile V-6 - ± - - - - - Clostridium difficile GAI# 10042 - ± - - - - - Clostridium difficile GAI# 10037 - ++ - - - - - Clostridium histlyticum Ccm5943 - - - - - - - Clostridium innocuum GAI#5472 - +++ - ± - - - Clostridium novyi (Type A) GAI#5614 - ++ - - - - - Clostridium paraputrificum V-96 - ++ - + + + + Clostridium paraputrificum R-13 - +++ - + + - - Clostridium paraputrificum R-78 - ++ - + + + + Clostridium perfringens GAI#5526 - ++ - ± ± ± ± Clostridium perfringens R-11 - + - ± ± ± ± Clostridium perfringens B-165-16 - + - ± ± ± ± Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Clostridium perfringens B-3-10 - + - ± ± ± ± Clostridium perfringens C-01 - + - ± ± ± ± Clostridium ramosum V-8 - +++ ± ++ ++ ++ ± Clostridium ramosum C-00 - +++ ± ++ ++ ++ ± Clostridium septicum GAI#7502 - ++ - ± ± - - Clostridium tertium GAI#5618 - ++ - + + ± ± Clostridium sordellii GAI#5612 - ± - - - - - Clostridium sporogenes GAI#5562 - - - - - - - Eubacterium aerofaciens R-6 - +++ ± - ± - - Eubacterium aerofaciens S-12 - +++ ± + + - - Eubacterium lentum R-7 - - - - - - - Eubacterium limosum R-9 - +++ - ± - - - Eubacterium limosum V-60 - ++ - ± - - - Eubacterium nitritogenes R-8 - +++ - ± ± - - Fusobacterium mortiferum GAI#5442 - + - - - - - Fusobacterium necrophrum GAI#5634 - ± - - - - - Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Fusobacterium russii GAI#0317 - ± - - - - - Fusobacterium varium GAI#5566 - + - - - - - Fusobacterium varium R-25 - ± - - - - - Megamonas hypermegas R-15 - +++ ++ ++ ++ + - Mitsuokella multiacida VI-71 - +++ +++ +++ +++ +++ + Mitsuokella multiacida VI-70 - +++ +++ +++ +++ +++ + Peptostreptococcus asacccharolyticus GAI#2356 - - - - - - - Peptostreptococcus asacccharolyticus R-22 - - - + + - - Peptostreptococcus magnus GAI#5528 - - - - - - - Peptostreptococcus micros GAI#5540 - - - - - - - Peptostreptococcus prevotii R-23 - - - ± - - - Peptostreptococcus productus X-45 - +++ + ++ ++ ++ ++ Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Propionibacterium acnes GAI#5648 - ++ - - - - - Propionibacterium granurosum R-20 - ++ - + ± ± - Veillonella parvura GAI#5602 - - - - - - - Veillonella parvura R-10 - - - - - - - Citrobacter diversus CIFL A0016 - ++ - + + - - Citrobacter freundii CIFL A0015 - ++ - + ± - - Enterobacter aerogenes CK121-1 - + + + + ± - Enterobacter cloacae CIFL A0001 - + - ± ± - - Enterococcus faecalis CIFL A0013 - +++ - ++ ++ ± + Enterococcus faecalis L-220 - +++ ++ ++ ++ - - Enterococcus faecalis ST-201 - +++ ++ ++ ++ ++ + Enterococcus faecium L-225 - +++ ++ ++ ++ - - Enterococcus faecium ST-101 - +++ ++ ++ ++ - - Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Escherichia coli CIFL A0008 - ++ - ± ± - - Escherichia coli I-3 - + - - - - - Escherichia coli O-1 - ++ - - - - - Escherichia coli M-1 - ++ - - - - - Escherichia coli U-1 - +++ ± ± + - - Klebsiella pneumoniae CIFL A0003 Klebsiella pneumoniae CK46 (1) - + + + + + - Lactobacillus acidophilus I-61 - +++ ++ +++ +++ ++ + Lactobacillus acidophilus I-68 - +++ + +++ +++ +++ +++ Lactobacillus casei I-139 - +++ - +++ +++ + - Lactobacillus casei II-8 - +++ - +++ +++ +++ +++ Lactobacillus fermentum CIFL A0066 - ++ - ± ± - - Lactobacillus fermentum JCM 1173 - +++ - ± + - - Lactobacillus gasseri JCM 1131 - +++ +++ +++ +++ + + Lactobacillus salivarius I-117 - + - ± - - - Lactobacillus salivarius I-108 - +++ +++ ++ ± - - Bacteria Tested strain Control Glucose Meioligo P OS-1 F-2 F-3 F-4 Morganella morganii ME138-1 - + - - - - - Proteins mirabilis ME14-(2) - + ± - - - - Proteins vulgaris CIFL A0011 - + ± ± - - - Serratia marcescens CIFL A0007 - + ± ± ± - - Staphylococcus aureus CIFL A0012 - ++ + + - - - Staphylococcus epidermidis CIFL A0018 - ++ ± - - - - Streptococcus haemolyticus CK6-2 - ++ ± ± - - - Streptococcus pyogenes CIFL A0017 - ++ - + ± - - Example 3 (Preparation of hard candies) In 500 mℓ of an aqueous 50% sucrose solution, 100 g of a concentrated solution of the gentiooligosaccharide having a solid content of 72% (w/w), obtained in (2) of Example 1 was dissolved with heating, and then the solution was concentrated under reduced pressure with heating until it came to have a water content of not more than 2%. In the resulting concentrate, 5 g of citric acid and small amounts of lemon perfume and colorant were mixed, and the mixture was molded by a conventional method to give hard candies. The resulting products were confirmed to be hard candies having a well harmonized taste of sweetness with bitterness, which was a novel taste. Example 4 (Preparation of lactic acid drink) After 500 g of skimmilk was sterilized with heating at 80°C for 20 minutes, the sterilized product was cooled to 40°C, followed by addition of 15 g of a starter to carry out fermentation at 35 to 37°C for 12 hours. Subsequently, the fermented product was homogenized, to which 50 g of a concentrated solution of the gentiooligosaccharide having a solid content of 72% (w/w), obtained in (2) of Example 1, 50 g of sucrose and 100 g of an high-fructose corn syrup were added, followed by sterilization at a temperature kept at 80°C. After cooling, a small amount of perfume was added, and then the product was bottled. The resulting product was confirmed to be a lactic acid drink having a well harmonized taste of flavor and bitterness with sourness. Example 5 (Preparation of a soft drink) To 500 mℓ of lemon juice squeezed from fresh lemons, 10 g of sucrose, 20 g of high-fructose corn syrup and 5 g of gentiooligosaccharide powder (OS-1) obtained in Example 1 were added, which were thoroughly mixed using a mixer, followed by filtration. Subsequently, the product was sterilized at a temperature kept at 70°C, thereafter cooled, and then bottled. The resulting product was confirmed to be a soft drink having a well harmonized taste of bitterness with sourness. Example 6 (Preparation of cookies) A base was prepared by mixing 50 g of weak flour, 30 g of margarine, 25 g of an egg, 0.5 g of baking powder, 25 g of first-grade white sugar, 10 g of gentiooligosaccharide powder (OS-1) obtained in Example 1 and 10 g of water. The base was baked at 170°C for 10 minutes according to a conventional method to give a product. The resulting product was confirmed to be cookies having a pleasant bitter taste and improved in flavor. Example 7 (Preparation of a jelly) Using 36 g of gelatin, 84 g of first-grade white sugar, 28 g of the concentrated solution of gentiooligosaccharide with a solid content of 72% (w/w), obtained in (2) of Example 1, 420 g of wine and 413 g of water, a jelly was prepared according to a conventional method. More specifically, the gelatin was previously swelled with water used in an amount of 1/2 of the prescribed amount, and the first-grade white sugar and the gentiooligosaccharide syrup were added to the remaining water, which were dissolved with heating and then boiled. The swelled gelatin was added thereto, and the mixture was again boiled. The resulting solution was cooled with ice water, the wine was added when the temperature of the solution fell to 50°C, and then the solution was further cooled. When the solution became viscous, the viscous solution was dividedly poured into cups. The cups were covered up, followed by solidification in a refrigerator kept at 5°C to give a product. The present product had a pleasant bitterness, rendering the taste of a high grade.

Claims: A medicinal composition for oral ingestion characterised in that it comprises at least one β-glucooligosaccharide and/or a reduced product thereof for use in promoting the growth of intestinal flora including Bifidobacteria and Lactobacillus acidophilus . A composition as claimed in claim 1 in the form of a food, drink or medicine. A composition as claimed in claim 1 or claim 2 wherein the β-glucooligosaccharide is cellobiose, sophorose, laminaribiose, gentiobiose, a 4-O-β-D-gentiooligosyl-D-glucose, or a 6-O-β-D-gentiooligosyl-D-glucose. A composition as claimed in claim 1 or claim 2 wherein the β-glucooligosaccharide and/or reduced product thereof is present in an amount of 0.5-50% by weight. A composition as claimed in claim 4 wherein the β-gluccooligosaccharide and/or reduced product thereof is present in an amount of 1.0 to 30% by weight. A composition as claimed in any one of claims 1 to 5 which comprises at least one additional sweetner. A composition as claimed in claim 6 wherein said sweetner is sucrose, corn syrup, glucose, maltose, high-fructose corn syrup, honey, sorbitol, maltitol, lactitol, L-aspertylphenylalanine methyl ester, saccharin, glycyrrhizin or stevioside. A composition as claimed in claim 1 containing dietary fibre, lactic acid bacteria, Bifidobacteria or vitamins. Use of a β-glucooligosaccharide and/or a reduced product thereof in the manufacture of nutritional or medicinal compositions for improving intestinal flora. Use as claimed in claim 9 wherein the β-glucooligosaccharide is cellobiose, sophorose, laminaribiose, gentibose, a 4-O-β-D-gentiooligosyl-D-glucose or a 6-O-β-D-gentiooligosyl-D-glucose.

Inventors: KAINUMA SEISHIRO, NAKAKUKI TERUO, OKADA GENTARO, UNNO TAKEHIRO, KAINUMA, SEISHIRO, NAKAKUKI, TERUO, OKADA, GENTARO, UNNO, TAKEHIRO
Applicants: JAPAN MAIZE PROD, NIHON SHOKUHIN KAKO CO., LTD.
Application year: 1990
Main classification: A23L1
IPC codes: A23L2, A23L1, A21D2, C12P19, A23C9, A23G3